Progesterone antagonists
Inventors
Nickisch, Klaus • Cessac, James • Narkunan, Kesavaram • Das, Baishakhi
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
Described herein are compounds which exhibit progesterone antagonistic effects and methods of treating cancer using such compounds.
Core Innovation
The patent describes a class of progesterone antagonists defined as progesterone-antagonist steroid structures according to formula (I) and formula (II), with variable substituents including R1 through R6 and/or R5. The steroid framework includes stereochemical α/β orientation, and the compounds are characterized by specified structural features, including examples designated as 1a through 1f with aryl/heteroaryl substitutions.
The compounds of formula (II) include a substituent selection in which R5 is defined as a particular heteroaryl group, including -3-furanyl and, in some embodiments, -3-pyridyl. The disclosure further describes multiple possible substituent options for R5 in the general progesterone-antagonist steroid family, together with the corresponding stereochemical framework. Pharmaceutically acceptable salts and progesterone-antagonist steroid compositions are also addressed.
The patent links the structural class to progesterone receptor antagonism for cancer therapy. Experimental evaluation of agonist/antagonist behavior is provided using cell-based progesterone receptor and glucocorticoid receptor reporter assays, including reporter gene system components and specific assay platforms. The disclosed results report progesterone antagonism with inhibition IC50 values relative to RU-486 and note minimal glucocorticoid antagonism for the tested examples.
Claims Coverage
The provided set includes two independent claims. The inventive coverage is concentrated on a specific chemical compound defined by formula (II) with R5 being -3-furanyl, and a pharmaceutical composition comprising inert carriers and a formula (II) compound where R5 is -3-furanyl or -3-pyridyl.
Formula (II) compound with -3-furanyl at R5
A compound of formula (II) where R5 is -3-furanyl.
Pharmaceutical composition with formula (II) compound and inert carriers
A pharmaceutical composition comprising one or more pharmacologically inert carriers and a compound of formula (II) where R5 is -3-furanyl or -3-pyridyl.
Across the independent claims, the core inventive subject matter is a formula (II) progesterone-antagonist steroid compound defined by the R5 substituent identity (-3-furanyl, and additionally -3-pyridyl for the composition claim), optionally formulated with pharmacologically inert carriers.
Stated Advantages
Progesterone antagonism is reported, with inhibition IC50 values relative to RU-486.
Minimal glucocorticoid antagonism is noted for the tested examples.
Documented Applications
Cancer therapy application is described in connection with progesterone receptor antagonism of the disclosed progesterone-antagonist steroid compounds.
Use of cell-based progesterone receptor and glucocorticoid receptor reporter assays is documented for evaluating agonist/antagonist behavior and receptor activity results.
Interested in licensing this patent?